Tone mix
Week by week 52 weeks
Share of Biohaven Ltd.'s 375 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 21, 2026 · tone +100Biohaven Ltd. (NYSE:BHVN) Given Average Rating of "Moderate Buy" by Brokerages+118
- Week of Sep 29, 2025 · tone +100Biohaven Ltd. (NYSE:BHVN) Given Consensus Recommendation of "Buy" by Brokerages+112
- Week of Aug 24, 2026 · tone +100Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy+99
- Week of Jul 6, 2026 · tone -50Why Wall Street Is Growing More Cautious on Biohaven (BHVN)-99
- Week of May 19, 2025 · tone +100Why Biohaven Stock Dove by Nearly 20% on Thursday+86
- Week of Oct 12, 2026 · tone +91Eyes on Asia: TCGX, Biohaven, Roche+78
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Biohaven Ltd. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 7 | +57 |
| Last 30 sessions | 15 | +66 |
| Last 90 sessions | 60 | +7 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Tuesday, October 27, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletBiohaven's BHV-1420 Targets PLA2R Autoantibodies In Membranous NephropathyNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Biohaven's BHV-1420 Targets PLA2R Autoantibodies In Membranous Nephropathy | www.rttnews.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
6 headlines, average tone +67: 4 positive, 2 neutral and 0 negative. Showing all 6.
- www.insidermonkey.com · 1 outletBiohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradePositive
- www.rttnews.com · 1 outletBiohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock UpPositive
- www.ibtimes.com.au · 1 outletBiohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaPositive
- www.rttnews.com · 1 outletBiotech Stocks Rally: BHVN Jumps 31%, KRRO Climbs 25%, ATNM And VCRE GainPositive
- www.biopharmadive.com · 1 outletBiohaven's previously rejected rare disease drug to get fresh FDA reviewNeutral
- www.themarketsdaily.com · 1 outletBiohaven Sees Unusually Large Options Volume (NYSE:BHVN)Neutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade | www.insidermonkey.com | 1 | Positive |
| Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock Up | www.rttnews.com | 1 | Positive |
| Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug Vyglxia | www.ibtimes.com.au | 1 | Positive |
| Biotech Stocks Rally: BHVN Jumps 31%, KRRO Climbs 25%, ATNM And VCRE Gain | www.rttnews.com | 1 | Positive |
| Biohaven's previously rejected rare disease drug to get fresh FDA review | www.biopharmadive.com | 1 | Neutral |
| Biohaven Sees Unusually Large Options Volume (NYSE:BHVN) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone +91: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.bioxconomy.com · 1 outletEyes on Asia: TCGX, Biohaven, RochePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Eyes on Asia: TCGX, Biohaven, Roche | www.bioxconomy.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 9, 2026
3 headlines, average tone +99: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.newswiretoday.com · 2 outletsOno Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in... - Pharma / BioTech / Nutrition - ONO Pharmaceutical Co., LtdPositive
- hartfordbusiness.com · 1 outletBiohaven signs licensing deal with Japanese drugmaker worth up to $100MPositive
- www.pharmaceutical-business-review.com · 1 outletBiohaven partners with Ono in $100m IgG degrader dealPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in... - Pharma / BioTech / Nutrition - ONO Pharmaceutical Co., Ltd | www.newswiretoday.com | 2 | Positive |
| Biohaven signs licensing deal with Japanese drugmaker worth up to $100M | hartfordbusiness.com | 1 | Positive |
| Biohaven partners with Ono in $100m IgG degrader deal | www.pharmaceutical-business-review.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 8, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.prnewswire.com · 1 outletBiohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseasePositive
- www.rttnews.com · 1 outletBiohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian MarketsNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease | www.prnewswire.com | 1 | Positive |
| Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets | www.rttnews.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Biohaven Ltd., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.